Scholarlink

Purpose of Review <p>Immune checkpoint inhibitor (ICI)–associated myocarditis (ICI-M) is rare but often severe. Cardiac magnetic resonance imaging (CMR) can detect myocardial edema and injury as well as fibrosis, yet its role in the setting of ICI-M remains uncertain. This review evaluates recent evidence on CMR findings, prognostic markers, and practical limitations in ICI-M.</p> Recent Findings <p>T1/T2 mapping and strain analysis may detect myocardial involvement not evident with conventional measures, but sensitivity is variable and affected by scan timing, prior therapies, and protocol heterogeneity. Prognostic associations have been reported for elevated native myocardial T1, septal late gadolinium enhancement (LGE), and impaired strain, though not consistently. In oncology patients, interpretation is further complicated by potential baseline myocardial abnormalities.</p> Summary <p>While CMR can contribute to the diagnostic work-up and risk assessment of ICI-M, current evidence is inconsistent and hampered by methodological limitations. CMR should be timely and findings should be interpreted alongside clinical, biological, ECG, echocardiographic and pathology data. Standardized multicenter prospective studies are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Myocarditis: Diagnostic and Prognostic Evidence and Limitations

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Joe-Elie Salem,
  • Lauren A. Baldassarre,
  • Alban Redheuil,
  • Samia Boussouar,
  • Paaladinesh Thavendiranathan,
  • Adrien Procureur

摘要

Purpose of Review

Immune checkpoint inhibitor (ICI)–associated myocarditis (ICI-M) is rare but often severe. Cardiac magnetic resonance imaging (CMR) can detect myocardial edema and injury as well as fibrosis, yet its role in the setting of ICI-M remains uncertain. This review evaluates recent evidence on CMR findings, prognostic markers, and practical limitations in ICI-M.

Recent Findings

T1/T2 mapping and strain analysis may detect myocardial involvement not evident with conventional measures, but sensitivity is variable and affected by scan timing, prior therapies, and protocol heterogeneity. Prognostic associations have been reported for elevated native myocardial T1, septal late gadolinium enhancement (LGE), and impaired strain, though not consistently. In oncology patients, interpretation is further complicated by potential baseline myocardial abnormalities.

Summary

While CMR can contribute to the diagnostic work-up and risk assessment of ICI-M, current evidence is inconsistent and hampered by methodological limitations. CMR should be timely and findings should be interpreted alongside clinical, biological, ECG, echocardiographic and pathology data. Standardized multicenter prospective studies are needed.